Pure Global AI
NCT06339086Not yet recruiting

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin
Chengdu Brilliant Pharmaceutical Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
Semaglutide Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd.
Timeline & enrollment
Phase
Phase 3
Start date
Apr 01, 2024
End date
Dec 30, 2025
Enrollment
478 participants
Primary outcome

Change in HbA1c

Summary

The goal of this clinical trial is to evaluate the similarities in efficacy and safety of
 semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic
 control after metformin treatment.
 
 Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous
 injection) as add-on to metformin for 32 weeks.
 
 Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the
 efficacy, safety, pharmacokinetics, and immunogenicity of them are similar.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06339086
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06339086 through Pure Global AI's free database. This Phase 3 trial is sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 478 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.